{
    "ticker": "OCX",
    "name": "OncoCyte Corporation",
    "description": "OncoCyte Corporation is a biotechnology company focused on the development and commercialization of groundbreaking cancer diagnostic tests. Founded in 2014 and headquartered in Alameda, California, OncoCyte aims to provide innovative solutions to improve cancer detection, prognosis, and treatment monitoring. The company specializes in developing non-invasive tests that utilize advanced genomic and proteomic technologies to identify cancer at an early stage, which is crucial for successful treatment outcomes. OncoCyte's flagship product, DetermaRx, is a tissue-based test that helps determine the likelihood of recurrence in patients with early-stage lung cancer, thereby assisting oncologists in making informed treatment decisions. The company is dedicated to enhancing patient care through precision medicine and leveraging its proprietary biomarker platform to discover and develop new diagnostic products. With a strong commitment to scientific research and clinical validation, OncoCyte continues to expand its product pipeline and partnerships with healthcare providers and institutions to transform the landscape of cancer diagnostics.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Alameda, California, USA",
    "founded": "2014",
    "website": "https://www.oncocyte.com",
    "ceo": "Bill Annett",
    "social_media": {
        "twitter": "https://twitter.com/OncoCyte",
        "linkedin": "https://www.linkedin.com/company/oncocyte/"
    },
    "investor_relations": "https://investors.oncocyte.com",
    "key_executives": [
        {
            "name": "Bill Annett",
            "position": "CEO"
        },
        {
            "name": "Michael B. D. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Diagnostics",
            "products": [
                "DetermaRx",
                "DetermaCyt"
            ]
        }
    ],
    "seo": {
        "meta_title": "OncoCyte Corporation | Innovative Cancer Diagnostics",
        "meta_description": "OncoCyte Corporation is dedicated to developing advanced cancer diagnostic tests to improve patient care and treatment outcomes. Explore our innovative solutions.",
        "keywords": [
            "OncoCyte",
            "Cancer Diagnostics",
            "Oncology",
            "DetermaRx",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is OncoCyte known for?",
            "answer": "OncoCyte is known for developing innovative cancer diagnostic tests that aid in early detection and treatment monitoring."
        },
        {
            "question": "Who is the CEO of OncoCyte?",
            "answer": "Bill Annett is the CEO of OncoCyte Corporation."
        },
        {
            "question": "Where is OncoCyte headquartered?",
            "answer": "OncoCyte is headquartered in Alameda, California, USA."
        },
        {
            "question": "What are OncoCyte's main products?",
            "answer": "OncoCyte's main products include DetermaRx and DetermaCyt."
        },
        {
            "question": "When was OncoCyte founded?",
            "answer": "OncoCyte was founded in 2014."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRA",
        "GHDX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "ILMN",
        "VRTX"
    ]
}